<DOC>
	<DOCNO>NCT00905398</DOCNO>
	<brief_summary>Patients acute lymphoblastic leukemia positivity breakpoint cluster region-Abelson murine leukemia ( BCR-ABL ) protein Philadelphia chromosome poor prognosis standard chemotherapy . The prognosis seem improve follow adition imatinibe , BCR-ABL inhibitor , treatment still substantial amount patient relapse progress treatment . Nilotinib BCR-ABL inhibitor potent imatinib . It show effective cell bear mutation BCR-ABL protein lead resistance imatinibe . The investigator ' hypothesis addition nilotinib standard chemotherapy acute lymphoblastic leukemia ( ALL ) translate rapid BCR-ABL reduction effectiveness imatinib-resistant clone lead less relapse well survival .</brief_summary>
	<brief_title>Nilotinib With Chemotherapy Treatment Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Diagnosis Acute Lymphoblastic Leukemia ( ALL ) BCRABL positive positive PCR ( central Lab ) No previous treatment ALL except corticoid cyclophosphamide less 600 mg/m2 Must able swallow tablet Lab result within normal limit ( Potassium , Calcium , Magnesio , Phosphorus , Transaminases , Alkaline Phosphatase , Bilirrubine , Amylase , Lypase ) Heart disease Interval QTc Fridericia &gt; 480 msec Coumadin use Pregnancy PS = 4 Previous medical history etilism or/and pancreatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Acute</keyword>
	<keyword>Philadelphia</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Treatment</keyword>
</DOC>